-
1898年法国Marie Curie和Pierrr Curie发现了镭,并发现其能够治疗有病的细胞,因此提出了放射治疗的名词[1]。随后放射治疗在医学领域得到了深入的研究。1914年法国Pasteau和Degrais首次使用镭管经尿道插植粒子治疗前列腺癌,开启了前列腺癌放射性粒子治疗的先河[2]。组织间近距离放射性粒子植入是将具有包壳的放射性核素直接植入到肿瘤组织内,通过放射性核素持续释放射线达到对肿瘤细胞杀伤的目的[3-4]。随着影像学技术的飞速发展,体外定位越来越精确,介入术也得到了有力的支持。20世纪80年代,粒子植入术引入我国后,在颅内、头颈部、肺部、腹部及盆腔多部位肿瘤中进行了探索性拓展,并取得了令人鼓舞的肿瘤局部控制率,显示出了非常好的应用前景[5]。随着认识的不断深入,临床工作者对这项治疗手段在术前计划、手术规范、适行模板、穿刺针插值、布源、术后放射剂量监测、疗效监测等方面提出了更高的要求。
组织间近距离放射性粒子植入治疗肿瘤的进展
Organizational close radioactive seed implantation therapy in treating tumor progression
-
摘要: 组织间近距离放射性粒子植入从最初的对前列腺肿瘤的治疗到对多器官肿瘤的治疗,在临床实践中,其技术不断成熟完善,取得了良好的治疗效果,成为肿瘤治疗的常规手段。在它不断发展的过程中,影像学的进步对肿瘤生物学行为的评估起到了至关重要的作用。随着手术的规范化、模板技术的进展、穿刺准确性的提高、粒子布源的个性化的发展,治疗计划系统对粒子植入的剂量计算及术后评价意义成为促进粒子植入术发展的新议题。组织间近距离放射性粒子植入治疗肿瘤技术是一项多学科相互协作的边缘学科,任何一个学科的进步都会给治疗带来新的认识。Abstract: Interstitial radioactive particles implantation from close range from the initial treatment of prostate cancer to the treatment of multiple organ tumors, in clinical practice, perfect in technology continues to mature, has obtained the good curative effect, become a routine method in tumor treatment. In the process of its continuous development, the progress of imaging for assessment of tumor biological behavior played a vital role. With the progress of the operation of standardization and template technology, puncture accuracy improvement, particle source personalized development, treatment planning system implantation dose calculation and postoperative evaluation of the significance of the particles is become a new issue to promote the development of particle implantation. Organizations close radioactive particles implantation tumor treatment technology is a multidisciplinary cooperation edge discipline, the progress of any one discipline will bring new understanding of treatment.
-
Key words:
- Brachytherapy /
- Neoplasms /
- Radiotherapy planning /
- computer-assisted
-
[1] Trombetta MG, Colonias A, Makishi D, et al. Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy in cancer of the lung[J]. Brachytherapy, 2008, 7(1):50-54. [2] Chassagne D, Court B, Gerbaulet A, et al. Cancer of the prostate:technics of curietherapy. Review of the literature and experience at the Institut Gustave-Roussy[J]. Bull Cancer, 1985, 72(6):578-584. [3] 于香红, 李振家, 窦卫涛, 等. CT引导下125I放射性粒子植入治疗隔顶部原发性肝癌价值的探讨[J].医学影像学杂志, 2013, 23(10):1575-1578.
[4] Older RA, Synder B, Krupski TL, et al. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy[J]. J Urol, 2001, 165(5):1590-1592. [5] Darakchiev BJ, Albright RE, Breneman JC, et al. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme[J]. J Neurosurg, 2008, 108(2):236-242. [6] 杨景魁, 吕金爽, 阎卫亮, 等.放射性粒子植入治疗不能手术的早期非小细胞肺癌疗效分析[J].中国肿瘤临床, 2014, 41(17):1111-1114.
[7] Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2):327-333. [8] 柴树德, 王俊杰, 申文江, 等.放射性粒子植入治疗胸部肿瘤[M].天津: 天津科学技术出版社, 2007: 37-39.
[9] 王娟, 王绍其, 徐建彬, 等. 125I粒子不同分布组织间植入对荷人胃癌裸鼠移植瘤疗效的影响[J].中华核医学杂志, 2008, 28(5):313-316.
[10] Liao A, Wang J, Wang J, et al. Relative biological effectiveness and cell-killing efficacy of continuous low-dose-rate 125I seeds on prostate carcinoma cells in vitro[J]. Integr Cancer Ther, 2010, 9(1):59-65. [11] 谈瑞生, 朱永强, 施富强, 等. CT引导下125I放射性粒子植入治疗恶性肿瘤19例分析[J].重庆医学, 2014, 43(1):106-109.
[12] 李振家, 王锡明, 武乐斌, 等. CT导向下组织间植入125I粒子治疗胰腺癌[J].中华肿瘤杂志, 2005, 27(3):187.
[13] No authors listed. Cancer statistics[J]. JAMA, 2013, 310(9):982. [14] Yoshioka Y. Current statue and perspectives of brachytherapy for prostate cancer[J]. Int J Clin Oncol, 2009, 14(1):31-36. [15] 吕金爽, 杨景魁, 郑广钧, 等. CT引导下放射性粒子植入治疗恶性纤维组织细胞瘤肺转移瘤临床疗效研究[J].中国肿瘤临床, 2013, 40(7):407-409.
[16] 王俊杰, 田素青, 李金娜, 等.放射性125I粒子平面永久插植布源剂量分布研究[J].中国微创外科杂志, 2005(12):1061-1062.
[17] Pickett B, Pouliot J. The effect of the radial function on 125I seeds used for permanent prostate implantation[J]. Med Dosim, 2004, 29(3):204-209. [18] 杨文彬, 王磊, 刘娜, 等.局部碘-125放射性粒子植入治疗胰腺癌的疗效评价[J].西安交通大学学报:医学版, 2011, 32(4):481-486.
[19] 林征宇, 武乐斌, 李成利, 等.光学导航介入性MR的临床应用[J].中华放射学杂志, 2005, 39(7):740-742.
[20] Yen TL, Driscoll CL, Lalwani AK. Significance of House-Brackmann facial nerve grading global score in the setting of differential facial nerve function[J]. Otol Neurotol, 2003, 24(1):118-122. [21] Ling CC. Permanent implants using I-125 radiobiological considerrations based on the linear quadratic model[J]. Int J Radiat Oncol Biol Phys, 1992, 23(1):81-87. [22] 田素青.放射性粒子永久植入治疗非小细胞肺癌的研究[J].国际放射医学核医学杂志, 2007, 31(3):188-191.
[23] 张建国, 张杰, 宋铁砾, 等. 125I放射性粒子组织间植入治疗面神经受侵的腮腺恶性肿瘤初步临床观察[J].中华口腔医学杂志, 2008, 43(3):132-135.
[24] Park RL, Liberman FZ, Lee DL, et al. Iodine-125 seed implantation as an adjunct to surgery in advanced recurrent squamous cell cancer of the head and neck[J]. Laryngoscope, 1991, 101(4 Pt1):405-410. [25] 王娟, 张宏涛, 赵文清, 等. 125I粒子平面布源剂量学研究[J].中华核医学杂志, 2010, 30(5):339-342.
[26] Martinez-Monge R, Nag S, Nieroda CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver[J]. Cancer, 1999, 85(6):12l8-l225. [27] Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer:observed local control with implantation of I-125 brachytherapy seeds[J]. Ann Thorae Surg, 2003, 75(1):237-242. [28] Lee EK, Zaider M. Intraoperative dynamic dose optimization in permanent prostate implant[J]. Int J Radiat Oncol Biol Phys, 2003, 56(3):854-861. [29] 翁志成, 杨维竹, 江娜, 等. CT引导下125I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志, 2010, 19(7):535-539.
计量
- 文章访问数: 2862
- HTML全文浏览量: 1630
- PDF下载量: 6